An NDA for the antipyschotic Fanapta has been submitted.
Laboratory Corporation of America and Vanda Pharmaceuticals have partnered to develop and commercialize a series of diagnostic tests for genetic markers identified by Vanda in the course of its clinical development of Fanapta™ (iloperidone). This lead product candidate is an atypical antipsychotic for which the company recently submitted an NDA.
Vanda has identified a series of pharmacogenetic markers during the development of Fanapta. Under the terms of the collaboration, LabCorp will be Vanda’s exclusive commercialization partner for tests for genetic markers of the Fanapta program.
“Working with innovative companies like Vanda to commercialize predictive medicine tests is a critical strategic focus for LabCorp,” remarks Andrew J. Conrad, Ph.D., chief scientist and global head of clinical trials for LabCorp. “This collaboration represents a successful translation of a research-based assay into a valuable diagnostic test.”
